Synchronous Orbital and Gastric Metastasis of Invasive Lobular Breast Carcinoma, Mimic Primary Gastric Carcinoma-Case Report

Young Jin Choi1*, Young Duck Shin1, Young Jin Song, Ho Chang Lee2 and Seung-Myoung Son2

1Department of Surgery, Anesthesiology, Chungbuk National University College of Medicine, Cheongju, Korea
2Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea

Corresponding author: Choi YJ, Department of Surgery, Chungbuk National University College of Medicine, Seongbong-ro 410, Heungdeok-gu, Cheongju 361-783, Korea, Tel: +82-43-269-6459; Fax: +82-43-266-6037; E-mail: yj0139@naver.com

Rec date: February 11, 2016; Acc date: April 12, 2016; Pub date: April 19, 2016

Abstract

Breast carcinoma is the most common primary origin of orbital metastasis. Orbital metastasis occurs through hematogenous spread and predominantly involves the choroid. On the other hand, breast carcinoma metastasis to the stomach is relatively rare. Invasive lobular carcinoma has a high tendency to metastasis to the stomach than ductal carcinoma. We present a case of invasive lobular carcinoma of breast with synchronous presentation of orbital and gastric metastasis. Gastroscopy revealed diffuse schirrous mass with pyloric obstruction and the biopsy was poorly differentiated carcinoma, mimic primary gastric malignancy. But on immunohistochemistry, both orbital and gastric mass showed hormonal receptor positivity that is agreement with primary breast lesion. Clinical suspicion, repeated endoscopic procedures, and intimate histologic analysis including immunohistochemistry is necessary for appropriate diagnosis, which might help to avoid unnecessary surgical procedure owing to incorrect diagnosis.

Keywords: Breast neoplasms; Lobular carcinoma; Neoplasm metastasis; Stomach; Orbit

Background

Breast carcinoma is the most common malignancy in worldwide and also second leading malignancy in South Korean woman [1]. The survival rates have increased over the years, because loco-regional and adjuvant therapy including hormonal therapy, chemotherapy and targeted therapy has progressed.

But the prognosis of advanced and metastatic breast carcinoma have not been changed. The common site of metastasis from breast carcinoma is bone, lung and liver and metastasis to orbit and gastrointestinal (GI) tract is relatively rare.

But the most common primary malignancy metastasis to orbit is breast carcinoma and the detection rate has been increased due to development in imaging study [2]. Rather, metastasis to GI tract from breast carcinoma is relatively rare. Invasive lobular carcinoma (ILC) has a high tendency to metastasis to the stomach than ductal carcinoma [3].

Because gastric malignancy is prevalent in South Korea [1], it can be difficult to distinguish from primary gastric malignancy on clinical, endoscopic, radiologic and histopathological features and can lead to unnecessary operative procedures.

Here, we present a rare case of invasive lobular carcinoma of breast with coincidence presentation with orbital and gastric metastasis, mimic primary gastric malignancy.

And, we also review recent literature about the usefulness of immunohistochemical (IHC) analysis in distinguishing primary gastric malignancy and gastric metastasis from breast carcinoma.

Case Presentation

Figure 1: Images of Breast Ultrasonography, MRI and PET CT that shows two multiple irregular enhancing mass on right breast with axillary LN metastasis.

A 37-year-old woman visited with palpable right breast mass and left eyelid swelling developed 2 months before. She also had epigastric discomfort and there was history of repeated upper gastrointestinal (UGI) endoscopy 2 month before at local clinic and diagnosed as chronic gastritis on repeated endoscopic biopsy for pylorus thickening.
A 1.5 cm sized irregular hard mass was palpated on right outer breast and multiple fixed conglomerated lymph nodes (LNs) were palpated on right axilla. Breast magnetic resonance imaging (MRI) and ultrasonography (USG) showed 1.5 cm and 1 cm sized multifocal malignant mass on right upper outer breast and multiple axillary lymphadenopathy.

Core needle biopsy results obtained from right breast mass was invasive lobular carcinoma. Laboratory analysis including liver function test, serum protein and creatinine was normal. Hemoglobin was 12 g/dL and CEA and CA15-3 were 4.36 ng/mL and 34.59 U/mL, respectively. Abdomen pelvis USG showed negative finding except bilateral hydronephrosis. Positron emission tomography-computerized tomography (PET-CT) covering skull base to pelvic floor didn't show any distant metastasis except primary malignancy and metastatic axilla (Figure 1).

Orbital MRI showed infiltrating mass involving left extraconal and periorbital space and MRI guided incisional biopsy revealed metastatic adenocarcinoma from breast (Figures 2 and 5a).

For the purpose of palliation, she underwent right breast conserving surgery with level II axillary LN dissection. Postoperative histology showed completely excised 1.5 cm and 1 cm sized multifocal grade III invasive lobular carcinoma with clear resection margin and five out of 20 dissected LNs were positive of metastases.

IHC analysis revealed the cells were positive for both estrogen receptor (ER; 2+, 90%) and progesterone receptor (PR; 2+, 60%), and negative for E-cadherin and c-erb-B2 (Figure 3).

Additional IHC analysis showed positive for gross cystic disease fluid protein-15 (GCDFP-15) and negative for CDX-2, MUC-2, MUC-5.

About one month after surgery, she complained of recurrent epigastric fullness and pain. Repeated UGI endoscopy was preceded and there was diffuse schirrous mass on prepyloric antrum with pyloric obstruction.

Abdominal CT showed a gastric wall thickening around pylorus with impeding pyloric obstruction without any obvious LN enlargement or metastatic spread; this was staged as T3 N0 M0 gastric malignancy (Figure 4).
The patient did not have any family history of breast and gastric cancer. She did not have a prior history of lobular carcinoma in situ and had not been on hormonal replacement therapy.

After a multidisciplinary discussion, we have decided not to precede further surgical intervention for gastric lesion and the patient underwent pyloric stent insertion to symptom control. Systemic chemotherapy composed of paclitaxel (80 mg/m²) and trastuzumb (2 mg/kg) was delivered weekly. After 24 courses of chemotherapy, left orbital mass was decreased and foreign body sensation was improved. Because the eye symptoms was improved, she did not proceed with orbital radiotherapy. Currently, since 18 months after initial treatment, she is under chemotherapy without change in regimen and orbital CT and endoscopic examination revealed that she has been showing partial response. She respond well to treatment with symptomatic improvement.

Discussion

About one-third of all orbital tumors are malignant and metastasis from breast carcinoma account for 28–58% of ocular and orbital metastasis. The orbital metastasis is detected as first sign of malignant disease or metastatic spread from breast carcinoma in about 10–30% of patients. Clinical presentation of orbital metastasis are diplopia, pain, blurred vision, exophthalmus, and a visible or palpable mass in the orbital or periorbital region, that was due to infiltration of cancer cell to extraocular muscle and orbital fat [4]. The histologic features of primary breast carcinoma can vary, and the pathologic findings of orbital metastases may also differ from the primary tumor. In this case, the main presentation of orbital metastasis was eyelid swelling and foreign body sensation and she didn’t complain any other blurred vision or pain. Orbital metastasis represents hematogenous spread and the main treatment is palliative. The aim of treatment is improve quality of life and preserve visual activity. Main treatment option is radiotherapy and 60–80% of patient showed improvement in blurred vision. Generally, the patient with orbital metastasis have poor prognosis. In this case, initially, she had the plan to undergoing radiotherapy after palliative primary breast surgery [5].

Rather, gastric metastasis from breast carcinoma is relatively rare and the incidence has been estimated as 2–18%. Most cases are diagnosed as one of the metastatic lesion out of multiple distant metastases. Clinical presentations include anorexia, early satiety, epigastric pain, bleeding and vomiting and in this case, she complained of dyspepsia and epigastric fullness in relation to the pyloric obstruction [6]. As seen in this case, metastatic gastric lesion show limitsplasia with diffuse infiltration of the muscularis propria and submucosa and rarely, external compression or discrete nodules may occur. Taal et al. [6] reported that 83% of patients with gastric metastasis had lobular histology as the primary breast pathology and the diffuse infiltration of stomach is the characteristic of metastasis from invasive lobular carcinoma of breast.

In this case, we thought the gastric lesion as primary gastric carcinoma. But clinical suspicion and endoscopic reevaluation, radiologic evaluation and discrete pathologic evaluation identified metastatic tumors and we can avoid unnecessary operative procedures. Macroscopic endoscopic evaluation is unhelpful in distinguishing primary and metastatic gastric malignancy. Endoscopic study may be normal in 50% of case, because gastric infiltration is frequently limited to the submucosa and seromuscular layer [7]. In this case, she diagnosed as chronic gastritis on previous repeated endoscopic biopsy, this may be originated from not doing deep submucosal biopsy. Deep and extensive biopsies and careful and comparative histologic analysis should be needed. However, lobular carcinoma of the breast may show signet ring cell morphology, this can be confused with a primary signet ring or diffuse-type gastric adenocarcinoma. Differentiation of a primary gastric poorly differentiated or signet ring cell carcinomas, from metastatic breast carcinomas may be difficult based on the histologic findings of the tumor. Diffuse type gastric adenocarcinomas and lobular carcinomas of the breast share a variety of cytomorphologic features, such as a single cell growth pattern and a signet ring cell appearance. However, primary and metastatic carcinomas of the GI tract have significantly different treatment and prognoses [8].
Detailed IHC study is the most helpful method in this case. Connell et al. [9] compared the IHC findings between primary gastric malignancy and metastatic gastric malignancy from breast carcinoma. Highly significant proportions of metastatic breast carcinomas were positive for ER (72%), PR (33%), GCDFP (78%), and CK5/6 (61%) compared with primary gastric carcinomas (ER, 0%; PR, 0%; GCDFP, 0%; and CK5/6, 14%). Especially, ER, PR, and GCDFP were 100% specific. Meanwhile, there were no significant differences with any of the other immunostains (c-erb-B2, CK7, and MUC3) between the primary and metastatic lesions [10].

There were principal breast restricted markers currently in clinical use. ER expression can be powerful sensitive markers that can differentiate metastatic breast cancers. But it had low sensitivity (~50%) and specificity in metastatic lesions and furthermore, ER is expressed in a wide subset of non-breast carcinomas including endometrium and ovary. In contrast, ER expression is exceedingly rare in adenocarcinoma of GI tract, especially colorectal cancer. However, increased ER and PR have also been described in gastric adenocarcinoma in limited cases [11]. Gross cystic disease fluid is a pathological secretion from breast and GCDFP-15 expression is one of the breast specific markers with the range of sensitivity with 11% to 73% and specificity with 93% to 100%. GCDFP-15 is not entirely breast restricted and expressed in apocrine gland origin malignancy including salivary glands, vulva, eyelids and tracheobronchial tree. Some gynecologic adenocarcinoma can also express GCDFP-15 (5–10%), but the vast majority of GI tract are almost always negative. Mammoglobin and GATA expression are also breast specific markers which range of sensitivity with 26% to 84% and 32% to 95%, respectively [12].

Conversely, CK 7 and CK 20 are useful cytokeratin markers for distinguishing carcinoma of metastatic and primary gastric lesion. CK 7+/CK20- phenotype is expressed in most breast, lung, and ovarian adenocarcinomas, whereas most intestinal adenocarcinomas are CK7-/ CK20+. Additionally, homeobox protein CDX 2 which required for intestinal organogenesis and encoding nuclear transcription factors involved in the proliferation and differentiation of intestinal epithelium is expressed mainly in GI malignancy, 61% of gastric cancers and 97% of colorectal cancers [13]. We didn’t analyzed the expression of CK 7 and CK 20 in this patient, but positive expression of GCDFP-15, ER, PR, negative expression of CDX-2 is the critical finding for the diagnosis of metastatic breast carcinoma to stomach.

Curtit et al. [14] compared IHC findings between primary breast malignancy and metastatic lesion after treatment. Forty two patients showed discordance on IHC analysis, a switch in receptor status was verified for ER in 17% and PR in 29%. In contrast, c-erb-B2 showed only 4% discordance rate. Chemotherapy, and especially anthracycline-based chemotherapy, was associated with switch in ER status [14]. In this case, ER and PR showed positive on metastatic gastric lesion that is agreement with primary breast disease; consistent with metastatic breast carcinoma. Rather, c-erb-B2 was expressed only in metastatic gastric lesion, this enables possibility of c-erb-B2 targeted therapy in addition to hormonal therapy and chemotherapy.

Hereditary gastric cancers account for 1-3% of gastric cancer cases. Among them, hereditary diffuse gastric cancer (HDGC) is an inherited autosomal dominant syndrome, which caused mainly by E-cadherin gene (CDH 1) germline mutation. There is an association of HDGC with lobular breast cancer and the International Gastric Cancer Linkage Consortium (IGCLC) has established the clinical criteria for CDH 1 genetic testing [15]. According to consensus guideline, the patient with diffuse gastric cancer with history of lobular breast cancer should be informed about genetic screening. But, present case concluded as primary lobular breast cancer with gastric metastasis and the patient did not have any family history of breast and gastric cancer. So, we did not proceed any further genetic testing.

Conclusion

The case of our patient showed synchronous presentation of orbital and gastric metastasis from invasive lobular breast carcinoma mimicking primary gastric malignancy. Clinical suspicion, repeated endoscopic procedures, and intimate histologic analysis including IHC are necessary for appropriate diagnosis and treatment, which might help to avoid unnecessary surgical procedure owing to incorrect diagnosis.

References